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increased abundance of 
proteobacteria in aggressive 
crohn’s disease seven years after 
diagnosis
M. K. Vester-Andersen1,2, H. C. Mirsepasi-Lauridsen3, M. V. prosberg1, C. O. Mortensen  5,  
c. träger5, K. Skovsen5, T. thorkilgaard5, C. nøjgaard1, I. Vind1, K. A. Krogfelt  3,4, 
n. Sørensen6, F. Bendtsen1 & A. M. petersen  1,7
Intestinal dysbiosis in inflammatory bowel disease (IBD) patients depend on disease activity. We 
aimed to characterize the microbiota after 7 years of follow-up in an unselected cohort of IBD patients 
according to disease activity and disease severity. Fifty eight Crohn’s disease (CD) and 82 ulcerative 
colitis (UC) patients were included. Disease activity was assessed by the Harvey-Bradshaw Index for CD 
and Simple Clinical Colitis Activity Index for UC. Microbiota diversity was assessed by 16S rDNA MiSeq 
sequencing. In UC patients with active disease and in CD patients with aggressive disease the richness 
(number of OTUs, p = 0.018 and p = 0.013, respectively) and diversity (Shannons index, p = 0.017 and 
p = 0.023, respectively) were significantly decreased. In the active UC group there was a significant 
decrease in abundance of the phylum Firmicutes (p = 0.018). The same was found in CD patients with 
aggressive disease (p = 0.05) while the abundance of Proteobacteria phylum showed a significant 
increase (p = 0.03) in CD patients. We found a change in the microbial abundance in UC patients with 
active disease and in CD patients with aggressive disease. These results suggest that dysbiosis of the gut 
in IBD patients is not only related to current activity but also to the course of the disease.
The potential role of the gut microbiota as a driver of the inflammatory process in inflammatory bowel diseases 
(IBD) has gained increasing attention in the past decades and the body of research in this field has expanded 
vastly. The aetiology of IBD is unknown but is generally believed to result from complex interactions between the 
immune system, the gut microbiota and environmental factors in genetic susceptible individuals1.
Several studies have found an imbalance in the gut microbiota in IBD patients compared to non-IBD controls 
with an overall loss of diversity, a depletion of firmicutes2–7 and an increase of Proteobacteria8–11. In Crohn’s dis-
ease (CD) the primary finding has been a decrease in abundance of Faecalibacterium prausnitzii (Firmicutes)2,12–15 
a butyrate-producing bacteria as well as an increase in the adherent-invasive E. coli (Proteobacteria)8,16–18, the 
latter particularly found to be linked to ileal Crohn’s disease. Studies in ulcerative colitis (UC) have been less 
consistent2,14,19–22. Yet, we have previously shown that E. coli play an important role in IBD pathogenesis in UC 
patients23–25. However, fecal microbiota transplantation (FMT) appears to be effective for induction of remission 
in UC as described in a recent meta-analysis of four placebo controlled trials26. These findings do support that 
intestinal dysbiosis play an important role as trigger of inflammation also in UC.
The clinical course of IBD is characterized by periods of active inflammation superseded by periods of remis-
sion. The phenotypic appearance of both CD and UC influences the choice of treatment and prognosis. CD 
patients with ileal disease are at higher risk of treatment with systemic steroids27 and surgery27–29 during the first 
flare of the disease. A recent study suggests that IBD can be subdivided into three phenotypes as ileal CD, colonic 
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CD and UC according to genetic composition30. Human studies on microbiota in IBD patients have shown a 
positive correlation between the NOD2 risk allele and the relative abundance of Enterobacteriaceae in intestinal 
specimens from IBD patients31 and the study by Gevers et al. demonstrated differences in the mucosa-associated 
microbiome of ileal and rectal biopsies32. Furthermore, the course of disease comprising periods of quiescent 
disease with alternating periods of active disease and thereby repeating or changing medication regimens may 
also influence gut microbiota33–35 Thus, it is possible that different IBD phenotypes as well as disease course are 
associated to different specific microbial characteristics.
The aim of our study was to investigate if the former described dysbiosis could be recovered in a cohort 
of unselected patients with CD and UC diagnosed in 2003–04 in Copenhagen, Denmark. The cohort is well 
described through 7 years of follow-up with a complete phenotypic characterization based on endoscopic find-
ings, diagnostic procedures (MR/CT/US), medical treatment and surgical procedures36. Subsequently, we wished 
to characterize the microbiota according to disease activity state, disease severity and disease localization in the 
included population after 7 years of disease duration.
Results
Fecal microbiota from 58 UC patients and 82 CD patients and 30 healthy controls was successfully determined 
by 16S rDNA sequencing.
Diversity of the microbiota in relation to disease activity. When comparing patients with active dis-
ease (HB-score ≥ 5/SCCAI score ≥ 3) to patients with inactive disease, the richness (number of OTUs, p = 0.018) 
(Fig. 1a) and diversity (Shannon index, p = 0.017) (Fig. 1b) was lower in active compared to inactive UC patients. 
There were no significant differences between active and inactive CD.
The microbiota diversity of inactive IBD was comparable to healthy controls.
Phyla-level differences in abundance in relation to disease activity. When looking into differ-
ences in abundance in patients with active versus inactive disease, there was a significantly lower abundance of 
Firmicutes (p = 0.018) in UC patients with active disease compared to patients with inactive disease. In CD, the 
abundance of Verrucomicrobia was significantly increased (p = 0.038) and a tendency for a lower abundance of 
Bacteroidetes (p = 0.071) in patients with active disease (Fig. 2a–c).
Diversity and abundancy in relation to disease severity. According to our definition of disease sever-
ity (with aggressive disease being defined as ≥3 courses of systemic steroids (≥50 mg/day) and/or biological 
therapy (any doses) and/or surgical resection during the 7 years of follow-up) a significant decrease of richness 
Figure 1. (a) (Number of OTU’s) and (b) (Shannons Index). Diversity of microbiota according to disease 
activity in ulcerative colitis and Crohn’s disease. NA indicates controls. Individual observations are marked as 
block black dots.
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(number of OTUs, p = 0.013) and diversity (Shannon index, p = 0.023) in CD patients with an aggressive disease 
course was observed (Fig. 3a,b).
There was no change in richness and diversity observed between non-aggressive and aggressive disease for 
UC.
At the phylum-level there was a significant difference in the sequence abundance of a phylum according to 
disease severity in CD patients. The abundance of Firmicutes showed a significant decrease (p = 0.05) and the 
abundance of Proteobacteria (p = 0.03) a significant increase in CD patients with aggressive disease compared to 
CD patients with non-aggressive disease (Fig. 4a,b). There were no significant findings in the phyla-abundance 
among UC patients with aggressive disease compared to non-aggressive disease.
Diversity in patients with active disease in relation to extent/localization of disease. When 
looking at patients with active disease in relation to extent (UC) or localization (CD) of disease, we found no 
significant differences in richness and diversity (number of OTUs or Shannons Index) among either UC or CD 
patients.
Phyla-level differences in abundance in patients with active disease in relation to disease 
extent/localization. When comparing patients according to phenotype, we found no differences in abun-
dance among UC or CD patients with active disease compared to inactive disease according to localization of 
disease.
Figure 2. (a–c) Phyla-level differences in abundance according to disease activity state in UC and CD patients. 
NA indicates controls. Individual observations are marked as block black dots.
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Discussion
In this study, we wished to describe the microbiota of the gut in IBD patients after 7 years of disease duration and 
explore gut dysbiosis in an unselected group of IBD patients according to the course of disease. We found a sig-
nificant difference in microbial diversity in UC patients with active disease compared to inactive disease, as well 
as in CD patients with aggressive disease compared to non-aggressive disease. The abundance of Firmicutes was 
decreased in UC patients with active disease and in CD patients with aggressive disease. Also, in CD patients with 
aggressive disease, the abundance of Proteobacteria was increased. However, phenotypic presentation of disease 
did not seem to influence the microbial community of the gut.
We found a significantly lower diversity overall in patients with clinical active UC, with the microbial diver-
sity of patients with inactive disease being comparable to the one of healthy controls. When looking at the phy-
lum level the abundance of Firmicutes was decreased in UC patients with active disease as also observed in CD 
patients with an aggressive disease course. This is in accordance to previous studies14,19–21,37,38. F. praustnitzii 
belong to the phylum Firmicutes. A low count of these bacteria has previously been found to be associated to 
the risk of relapse in UC patients, and the F. praustnitzii population recovers in patients who achieve remis-
sion39. The association between gut microbiota and disease activity was also found in a recent meta-analysis, 
supporting our results40. In CD, a decrease in the population of Firmicutes have been found to be associated with 
relapsing disease compared with non-relapsing disease after discontinuation of TNF-alpha inhibitor treatment10. 
The increased abundance of Proteobacteria in CD patients found in our study has previously, in other studies, 
on a genus level mainly shown to be driven by an increase in the adherent-invasive E. coli in CD patients8,16,18. 
Furthermore, it was shown that pathogenic E. coli B2 phylogroup were isolated from feces of UC patients23–25. 
It has previously been shown that patients with extensive and active UC (based on SCCAI-scores) have a signif-
icantly higher level of Proteobacteria in mucosal biopsies compared with patients with limited extend and less 
active disease41. Our data do not support these findings.
In our study, we investigated if the severity of disease over time influenced the microbial community in 
incident CD and UC patients. Inception cohorts are characterized by encompassing unselected patients who 
represent the entire span of disease activity from a mild to a severe disease course., We did not have baseline 
microbiome data, thus by defining disease severity according to treatment regimens and surgery we aimed to 
investigate the effect of the longitudinal evolution of disease. We found a significant decrease in the number 
of OTUs when comparing CD patients with aggressive and non-aggressive disease. There were no changes 
observed for UC. At the phylum level we found Proteobacteria to be significantly more abundant in CD patients 
with aggressive disease compared with non-aggressive disease. Wills et al. has previously suggested that treat-
ment with thiopurines influence the microbial composition and diversity as they found a significant decrease 
in diversity among thiopurine users, no such association was found among users of steroids, anti-TNF alpha 
Figure 3. (a) (Number of OTU’s) and (b) (Shannons Index). Diversity of the microbiota according to disease 
severity. NA indicates controls. Individual observations are marked as block dots.
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inhibitors or users of amino salicylates. However, in the multivariate analysis the results did not reach signifi-
cance. Furthermore, the microbial shifts observed was on an inter-individual level and no significant difference 
in presence or relative abundance of any particular species or group was detected based on disease activity on a 
group level neither in the CD nor in the UC patients42. A newer prospective study in incident, treatment naïve 
pediatric IBD patients found that dysbiosis of the gut microbiota persisted after therapy, regardless of treatments 
and remission status34. Yet another study found that the dynamics of the microbiome composition was influenced 
by changes in medication but weakly correlated to disease activity33.
We have not analyzed the influence of different treatment regimens on the gut microbiota as we believe sub-
group analyzes will undermine the statistical power of the study due to small samples, however several medica-
tions have shown to impact gut microbiota43 including IBD specific medications33.
It is possible that patients in risk of relapse and thus in need of add-on therapy (medical or surgical) remain in 
a condition of dysbiosis over time.
In the study by Naftali et al., a comparison was made between a cohort of adult CD patients (called the MEIR 
cohort) and the RISK cohort consisting of treatment-naïve pediatric CD patients showing that the findings of 
decreased F. praustnitzii and increased Enterobacteriaceae characterizing ileal CD in the MEIR cohort was not 
observed in the RISK cohort. This lead to the assumption that microbial dysbiosis may be characteristic of adult 
onset disease or may develop during years of illness or treatment or both44.
Finally, we wished to investigate if disease phenotype influenced the microbiota. Naftali et al. showed that the 
phenotype (ileal, Ileocolonic or colonic disease) of CD determined the clustering of microbiomal taxa regardless 
of site of biopsy (terminal ileum or colon) or inflammatory state (inflamed or non-inflamed tissue). Furthermore, 
they found that ileal CD samples were richer in Escherichia (Proteobacteria), whereas colon-involving CD had 
higher levels of Faecalibacterium (Firmicutes) and 2 unidentified genera of the Clostridiales and Ruminococceae15. 
Gevers et al. also reported of this clustering of taxa within phenotype regardless of site of biopsy32. In the study by 
Willing, looking at dysbiosis of twins with IBD, more Firmicutes were found in CD patients with colonic disease 
compared to healthy, whereas patients with ileal disease tended to have fewer. Conversely, ileal CD patients had 
more Proteobacteria than healthy subjects, whereas this difference was not observed between colonic CD patients 
and healthy45. In addition, we found a significant increase in the abundance of Verrucomicrobia in CD patients 
with active disease. The impact of these findings are not clear and needs further research46.
The major strength of our study is the use of a population of unselected IBD patients from an inception 
cohort after 7 years of follow-up. The course of the disease on an individual level was thoroughly described by 
retrospective review of medical records with medical and surgical interventions being registered together with a 
thorough phenotypic description based on endoscopic and imaging examinations. The patients have, according 
to the natural history of the disease, within a wide margin, been exposed to different medications and surgery 
Figure 4. (a,b) Phyla-level differences in abundance according to disease severity in UC and CD patients. 
Individual observations are marked as block black dots.
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influencing the course of disease on an individual basis leading the cohort in different directions. Nevertheless, 
we have been able to show similar shifts in bacterial diversity and abundance as previously described in studies 
of small numbers including highly selected patients. Potential confounders such as diet, Bristol stool score, BMI 
and medication could influence results, as well as we, unfortunately, were not able to recruit all the patients to 
the follow-up visit despite vigorous efforts. Due to ethical guidelines in Denmark patients can only be contacted 
by letter and answer by a return letter, which may influence the reply rate. The study also has several limitations. 
We do not have baseline stool microbiota data, thus the results of dysbiosis and disease activity is cross sectional. 
We have no knowledge of stool consistency of the collected fecal samples. This could influence our results47. We 
also do not know whether patients subjective activity scores were due to other symptoms besides active IBD, 
such as irritable bowel syndrome symptoms, which could influence results48. Finally we did not supplement our 
activity scoring systems with biomarkers of activity such as fecal calprotectin or blood samples like albumin and 
C-reactive protein. It has been debated whether the sequencing of samples of mucosal versus stool origin impacts 
results. In the treatment-naïve CD patients in the RISK cohort, the microbiome profiles found in tissue samples, 
was not found in stool samples32. An endoscopic examination was not included in our follow-up visit, thus biopsy 
sampling was not an option, however, as mentioned in the study by Gevers32, it may not be the site of active 
inflammation that influences the microbial shifts, but the phenotypic appearance. Unfortunately, our study could 
not support this hypothesis due to low numbers. Larger cohorts of new-onset, treatment-naïve IBD patients have 
recently been established and shown remarkable results regarding changes in gut microbiome during the first year 
of disease34,35. It will be interesting to follow the long term effects of disease course on the gut microbiota in future 
follow-up studies of these cohorts.
conclusions
In this cohort of unselected IBD patients with 7 years of disease duration, we found shifts in the microbial com-
munity of the gut comparable to findings in studies of smaller numbers and highly selected patients. In the 
cross-sectional design taking disease activity into account, we could only find this change among UC patients. In 
the longitudinal design, taking the course of disease into account the shift was found in CD patients. We did not 
find any effect of phenotypic appearance. Our results support the hypothesis that not only disease activity influ-
ences the gut microbiota, but also that disease severity and treatment have a forwarded effect on the microbial 
community of the gut, as changes seem to be more persistent in CD patients with aggressive disease over time. 
However, it could also be speculated that shifts in the microbiota has a forwarded effect on disease severity.
Materials and Methods
Study population and sample collection. In 2003–04, 513 patients (300 UC, 213 CD) were diagnosed 
with IBD in a well-defined area of Copenhagen, Denmark and data were collected to implement an inception 
cohort49. In 2011–12, data on phenotypic changes, medical treatment and surgery were collected retrospectively 
by reviewing the medical records. The longitudinal retrospective follow-up did not include subjective data or 
biomarkers of disease activity. In 2011–12, patients were, by letter, invited to participate in a clinical follow-up 
visit (patients with mental illness, no Danish language skills, emigration, migration out of study area, wished not 
to be contacted or lost to follow- up and patients who died during follow-up were not contacted). 140 patients (82 
CD, 58 UC) were included in this study. Disease activity was assessed at the follow-up visit by validated scoring 
systems (Harvey-Bradshaw Index for CD (HB-score) and Simple Clinical Colitis Activity Index (SCCAI) for 
UC) and smoking status registered. Patients collected a fecal sample at home and sent it by mail to the laboratory 
where it was stored at minus 80 degrees Celsius until the analyses was performed.
A group of healthy subjects (n = 30) were used as controls. None of the controls had received antibiotics 3 
months prior to inclusion. We did not have data on diet, medication or BMI of the controls. As the controls were 
volunteered co-workers and students, no matching was performed. All the included participants gave informed 
written consent. Demographic and clinical characteristics of patients and healthy controls are summarized in 
Table 1. The details with regard to inclusion and exclusion in the follow-up study and disease course have previ-
ously been described36,49,
Definitions
Disease activity and severity. CD patients were scored with the HBI-score during the follow- up visit, 7 
years after inclusion50. HBI-score is a simpler score compared to the Crohn’s Disease Activity Index (CDAI) and 
consists of clinical parameters including: general well-being, abdominal pain, number of liquid stools per day, 
abdominal mass and extraintestinal manifestations. The HBI-Index provides the categorization of patients into 
different symptom groups: remission (HBI <5), mild disease (5–7), moderate disease (8–16) and severe disease 
(>16).
In UC patients, disease activity was assessed by the SCCAI-score questionnaire51. SCCAI is a symptom scor-
ing questionnaire, consisting of questions regarding: bowel frequency (day), bowel frequency (night), urgency of 
defecation, blood in stool, general well-being and extra-intestinal manifestations. Scoring range is between 0 and 
19. A SCCAI score of ≤2 was defined as remission, 3–5 as mild disease activity, 6–11 as moderately active disease 
and ≥12 as severely active disease. A score more than or equal to 3 was defined as active disease.
A severe disease course was defined as ≥3 courses of systemic steroids (≥50 mg/day) and/or biological ther-
apy (any dose) and/or surgical resection (CD patients) during the 7 years of FU.
IBD phenotype. The disease localization and behavior of CD were described according to the Vienna classi-
fication at diagnosis and during follow-up52. Maximum extent at follow-up was used in the analyses.
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The extent of disease in UC was defined as E1: proctitis (proximal extent to the sigmoid colon), E2: left sided 
(to the splenic flexure), or E3: extensive disease (beyond the splenic flexure)53. Maximum extent at follow-up was 
used in the analyses.
Laboratory work. DNA extraction. DNA was extracted using the PowerSoil DNA Isolation Kit (MO-BIO), 
which has previously been found to be well suited for fecal samples54. Negative controls were included from DNA 
extraction55. All plates included a mock community to serve as an internal control for calibration of the bioinfor-
matical pipeline.
The 16S rDNA V3-V4 region as targeted using the primers S-D-Bact-0341-b-S-17 and S-D-Bact-
0785-a-A-2156. These are universal bacterial 16S rDNA primers, which target the V3-V4 region. The follow-
ing PCR program was used: 98 °C for 30 sec, 25x (98 °C for 10 s, 55 °C for 20 s, 72 °C for 20 s), 72 °C for 5 min. 
Amplification was verified by running the products on an agarose gel. Indices were added in a subsequent PCR 
using the Nextera Index Kit V2 (Illumina) with the following PCR program: 98 °C for 30 sec, 8x (98 °C for 10 s, 
55 °C for 20 s, 72 °C for 20 s), 72 °C for 5 min. Attachment of barcodes was verified by running the products on an 
agarose gel.
Products from the nested PCR were pooled and the resulting library cleaned with the Agencourt AMPure 
XP PCR purification kit (Beckman Coulter). The DNA concentration of pooled libraries was measured on a 
Qubit fluorometer using the Qubit High Sensitivity Assay Kit (Thermo Fisher Scientific). Sequencing was done 
on an Illumina MiSeq desktop sequencer using the MiSeq Reagent Kit V3 (Illumina) for 2x 300 bp paired-end 
sequencing.
Characteristics UC n = 82 CD n = 58 Controls n = 30
Male/female % 35 (43)/47 (57) 24 (41)/ 34 (59) 12 (40)/18 (60)
Age (years), median, (range) at clinical follow-up 39.8 (24.9–81.2) 46.9 (21.0–72.9) 33.0 (18.8–53.9)
Medication during follow-up
5-Aminosalicylic acid/salazopurine (%) 67 (82) 41 (71)
Azathioprine/6-Mercaptopurine (%) 25 (30) 41 (71)
Corticosteroids (%) 41 (50) 43 (74)
Anti-TNF (%) 7 (8) 21 (36)
Medication at time of follow-up 5 NA 3 NA
Medication free (%) 20 (24) 20 (34)
5-Aminosalicylic acid/salazopurine (%) 52 63) 6 (10)
Azathioprine/6-Mercaptopurine (%) 10 (12) 21 (36)
Corticosteroids (%) 5 (6) 5 (9)
Anti-TNF (%) 1 (1) 7 (12)
Antibiotics 2 months prior to sampling 5 NA 2 NA
Yes (%) 12 (16) 2 (4) 0 (0)
Disease activity 1 NA
HB-index <5 (remission) (%) NA 49 (84)
HB-index ≥5 (active) (%) NA 9 (16)
SCCAI <3 (remission) (%) 59 (73) NA
SCCAI ≥3 (active) (%) 22 (27) NA
Disease extent (maximum) NA
Proctitis E1 (%) 20 (24) NA
Left-sided E2 (%) 33 (40) NA
Extensive E3 (%) 29 (35) NA
Disease localisation (maximum) NA
Terminal ileum L1 (%) 5 (9)
Colon L2 (%) 29 (50)
Ileocolon L3 (%) 16 (28)
Upper GI L4 (%) 8 (14)
Disease behaviour (maximum) NA
Inflammatory B1 (%) 36 (62)
Stricturing B2 (%) 9 (16)
PenetratingB3 (%) 13 (22)
Smoking at diagnosis (%)
Current 8 (10) 24 (41)
Former or never 74 (90) 34 (59)
Table 1. Demographic and clinical characteristics of the 140 IBD patients included and 30 controls in the study. 
N: number, (%): percentage of total, NA: not applicable.
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Bioinformatical analysis. The 64-bit versions of USEARCH 8.0.151757 and mothur v.1.35.158 was used in 
combination with several in-house programs for bioinformatical analysis of the sequence data. Following tag 
identification and trimming, all sequences from all samples were pooled. Paired end reads were merged, truncat-
ing reads at a quality score of 4, requiring at least 100 bp overlap and a merged read length between 300 and 600 bp 
in length. Sequences with ambiguous bases, without perfect match to the primers, or homopolymer length greater 
than 8 were discarded and primer sequences trimmed. Reads were quality filtered, discarding reads with more 
than 5 expected errors and sequences are strictly dereplicated, discarding clusters smaller than 5. Sequences were 
clustered into OTUs (operational taxonomical units) at 97% sequence similarity, using the most abundant strictly 
dereplicated reads as centroids and discarding suspected chimeras based on internal comparison. Additional 
suspected chimeric OTUs were discarded based on comparison with the Ribosomal Database Project classifier 
training set v959 using UCHIME60. Taxonomic assignment of OTUs was done using the method by Wang et al.61 
with mothur’s PDS version of the RDP training database v14. Following this, samples were rarified to the lowest 
sequence number found in a sample (2780).
Statistics. Statistical analyses were done in R. The data are given in numbers and percentages or median and 
ranges. Mann-Whitney U tests and Kruskal-Wallis tests were used for testing for significant differences between 
groups.
ethical considerations. All research was performed in accordance with hospital guidelines, and informed 
consent was obtained from all participants. The Regional Ethics Committee (The Capitol Region of Denmark) 
approved this study (H-1-2011-088) and permission was obtained from the Danish Data Registry (01769 
HVH-2012-027).
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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